Alpha 2.0
Login Register
» Authors » L Paz-Ares

L Paz-Ares

Explore the profile of L Paz-Ares including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 90
Citations 2419
Followers 0
Related Specialties
Oncology
General Medicine
Urology
Top 10 Co-Authors
H Cortes-Funes
E Felip
P Lianes
D Isla
P Garrido
M Hidalgo
R Garcia-Carbonero
J De Castro
M Lopez-Brea
J M Trigo
Published In
Ann Oncol
ESMO Open
Clin Transl Oncol
J Clin Oncol
Br J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Lung cancer research and treatment: global perspectives and strategic calls to action
Meyer M, Peters S, Mok T, Lam S, Yang P, Aggarwal C, et al.
Ann Oncol . 2024 Oct; 35(12):1088-1104. PMID: 39413875
Background: Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to review the current landscape of lung cancer research and...
2.
A potential therapeutic strategy based on acute oxidative stress induction for wild-type NRF2/KEAP1 lung squamous cell carcinoma
Sanchez-Ortega M, Garrido A, Cirauqui C, Sanz-Gonzalez L, Hernandez M, Gonzalez-Garcia A, et al.
Redox Biol . 2024 Aug; 75:103305. PMID: 39137583
Extensive efforts have been conducted in the search for new targetable drivers of lung squamous cell carcinoma (LUSC); to date, however, candidates remain mostly unsuccessful. One of the oncogenic pathways...
3.
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Felip E, Cho B, Gutierrez V, Alip A, Besse B, Lu S, et al.
Ann Oncol . 2024 Jun; 35(9):805-816. PMID: 38942080
Background: Amivantamab-lazertinib significantly prolonged progression-free survival (PFS) versus osimertinib in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer [NSCLC; hazard ratio (HR) 0.70; P < 0.001], including...
4.
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
Borghaei H, OByrne K, Paz-Ares L, Ciuleanu T, Yu X, Pluzanski A, et al.
ESMO Open . 2023 Nov; 8(6):102065. PMID: 37988950
Background: In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1%...
5.
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
Garon E, Reck M, Nishio K, Heymach J, Nishio M, Novello S, et al.
ESMO Open . 2023 Jun; 8(4):101580. PMID: 37390764
Background: Ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) over placebo + ERL (PBO + ERL) in the phase III RELAY study of patients with epidermal growth...
6.
Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation
Gosney J, Paz-Ares L, Janne P, Kerr K, Leighl N, Lozano M, et al.
ESMO Open . 2023 Jun; 8(4):101587. PMID: 37356358
Biomarker tests in lung cancer have been traditionally ordered by the treating oncologist upon confirmation of an appropriate pathological diagnosis. The delay this introduces prolongs yet further what is already...
7.
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
Simonelli M, Garralda E, Eskens F, Gil-Martin M, Yen C, Obermannova R, et al.
ESMO Open . 2022 Aug; 7(5):100562. PMID: 35987165
Background: The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there are no data on its efficacy in solid tumors. This phase I/II study (NCT03637764)...
8.
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik C, Tan D, et al.
Ann Oncol . 2022 Aug; 33(11):1168-1178. PMID: 35973665
Background: RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET inhibitor, previously demonstrated clinical activity in patients with...
9.
Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
Morfouace M, Novello S, Stevovic A, Dooms C, Janzic U, Berghmans T, et al.
Sci Rep . 2022 May; 12(1):8342. PMID: 35585228
Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients...
10.
Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al.
ESMO Open . 2022 Mar; 7(2):100408. PMID: 35279527
Background: In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell...